PL3121280T3 - Antysensowne kompozycje i sposoby ich wytwarzania i stosowania - Google Patents

Antysensowne kompozycje i sposoby ich wytwarzania i stosowania

Info

Publication number: PL3121280T3
Authority: PL; Poland
Prior art keywords: preparation; methods; antisense compositions; antisense; compositions
Prior art date: 2008-11-13

Application number

PL16187284.1T

Other languages

English (en)

Inventor

Sergio Baroni

Salvatore Bellinvia

Francesca Viti

Original Assignee

Nogra Pharma Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-13

Filing date

2009-11-13

Publication date

2025-09-01

2009-11-13 Application filed by Nogra Pharma Limited filed Critical Nogra Pharma Limited

2025-09-01 Publication of PL3121280T3 publication Critical patent/PL3121280T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Inorganic Chemistry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)

PL16187284.1T 2008-11-13 2009-11-13 Antysensowne kompozycje i sposoby ich wytwarzania i stosowania PL3121280T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08425727		2008-11-13
US15229709P	2009-02-13	2009-02-13

Publications (1)

Publication Number	Publication Date
PL3121280T3 true PL3121280T3 (pl)	2025-09-01

Family

ID=42101499

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL09756431T PL2364360T3 (pl)	2008-11-13	2009-11-13	Antysensowne kompozycje i sposoby ich wytwarzania i stosowania
PL16187284.1T PL3121280T3 (pl)	2008-11-13	2009-11-13	Antysensowne kompozycje i sposoby ich wytwarzania i stosowania

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL09756431T PL2364360T3 (pl)	2008-11-13	2009-11-13	Antysensowne kompozycje i sposoby ich wytwarzania i stosowania

Country Status (23)

Country	Link
US (7)	US8912154B2 (pl)
EP (2)	EP2364360B1 (pl)
JP (7)	JP5719776B2 (pl)
KR (2)	KR101767145B1 (pl)
CN (2)	CN102216458B (pl)
AU (4)	AU2009315898B2 (pl)
CA (2)	CA3085272A1 (pl)
CY (1)	CY1119140T1 (pl)
DK (2)	DK3121280T3 (pl)
ES (2)	ES2627745T3 (pl)
FI (1)	FI3121280T3 (pl)
HR (2)	HRP20250744T1 (pl)
HU (2)	HUE032368T2 (pl)
LT (2)	LT2364360T (pl)
MX (3)	MX346335B (pl)
NZ (1)	NZ592673A (pl)
PL (2)	PL2364360T3 (pl)
PT (2)	PT3121280T (pl)
RS (2)	RS56049B1 (pl)
RU (2)	RU2593939C2 (pl)
SI (2)	SI3121280T1 (pl)
SM (2)	SMT202500239T1 (pl)
WO (1)	WO2010054826A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITRM20030149A1 (it)	2003-04-02	2004-10-03	Giuliani Spa	Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2627745T3 (es)	2008-11-13	2017-07-31	Nogra Pharma Limited	Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
US9791442B2 (en)	2011-09-15	2017-10-17	Nogra Pharma Limited	Methods of monitoring responsiveness to anti-SMAD7 therapy
ITCO20120008A1 (it) *	2012-03-01	2013-09-02	Nuovo Pignone Srl	Metodo e sistema per monitorare la condizione di un gruppo di impianti
CN104487574B (zh) *	2012-04-18	2017-07-07	诺格尔制药有限公司	治疗糖尿病和/或促进胰岛移植后存活的方法
US20140122184A1 (en) *	2012-10-29	2014-05-01	Elwha Llc	Food Supply Chain Automation Grocery Information System And Method
US20150335763A1 (en) *	2013-01-09	2015-11-26	The Feinstein Institute For Medical Research	Hmgb1-binding beads and uses thereof
US10006029B2 (en)	2013-03-15	2018-06-26	Nogra Pharma Limited	Methods of treating colorectal cancer
EP2970419B8 (en) *	2013-03-15	2019-12-11	Nogra Pharma Limited	Methods of treating colorectal cancer
RU2016147569A (ru)	2014-05-09	2018-06-13	Ногра Фарма Лимитед	Способы лечения воспалительного заболевания кишечника
US11427600B2 (en)	2014-06-27	2022-08-30	Nogra Pharma Limited	Aryl receptor modulators and methods of making and using the same
US20170247695A1 (en)	2014-10-17	2017-08-31	Celgene Corporation	Isotopologues of smad7 antisense oligonucleotides
EP3213070A2 (en) *	2014-10-17	2017-09-06	Nogra Pharma Limited	Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US10337004B2 (en)	2014-10-17	2019-07-02	Nogra Pharma Limited	Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
MA41271A (fr) *	2014-12-26	2017-10-31	Celgene Alpine Invest Company Ii Llc	Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
JP6583954B2 (ja) *	2015-01-08	2019-10-02	日東電工株式会社	展示装置および映像展示方法
WO2016130832A1 (en) *	2015-02-13	2016-08-18	Idera Pharmaceuticals, Inc.	Toll-like receptor 9 antagonist and methods of use thereof
WO2017055611A2 (en) *	2015-09-30	2017-04-06	Nogra Pharma Limited	Methods of using smad7 antisense oligonucleotides based on biomarker expression
AU2016360956A1 (en)	2015-11-25	2018-06-07	Nogra Pharma Limited	IL-34 antisense oligonucleotides and methods of using same
US11162097B2 (en)	2016-02-23	2021-11-02	Nogra Pharma Limited	Methods of treating intestinal fibrosis using SMAD7 inhibition
US20190046490A1 (en)	2016-02-26	2019-02-14	Nogra Pharma Limited	Methods of treating lactose intolerance
WO2018111323A1 (en) *	2016-12-14	2018-06-21	Progenity Inc.	Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease
EP3554345A1 (en)	2016-12-14	2019-10-23	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
WO2018122376A1 (en)	2016-12-30	2018-07-05	Nogra Pharma Limited	Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
GB201707501D0 (en) *	2017-05-10	2017-06-21	Index Pharmaceuticals Ab	New therapy 2
US10517889B2 (en)	2017-09-08	2019-12-31	Ionis Pharmaceuticals, Inc.	Modulators of SMAD7 expression
WO2020152350A1 (en)	2019-01-25	2020-07-30	Nogra Pharma Limited	Compositions for use in preventing acne
EP3921299B1 (en)	2019-02-08	2024-11-20	Nogra Pharma Limited	Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
MX2021010255A (es)	2019-02-26	2021-12-15	Nogra Pharma Ltd	Oligonucleotidos que interferen con proteina de retraso mental de x fragil y metodos para usar los mismos.
CN114729363A (zh)	2019-11-15	2022-07-08	诺格拉制药有限公司	Il-34反义剂及其使用方法
CN115552005A (zh) *	2020-04-24	2022-12-30	诺格拉制药有限公司	Smad7反义寡核苷酸(aso)的组合物及其使用方法
CN117321206A (zh)	2021-05-17	2023-12-29	诺格拉制药有限公司	Il-34反义剂及其使用方法
EP4441224A4 (en)	2021-12-03	2026-03-11	Quralis Corp	Antisense oligonucleotides with modified skeletal chemicals
JP2026513538A (ja)	2023-03-28	2026-04-28	ノグラファーマリミテッド	回腸嚢炎を処置するためのｓｍａｄ７阻害性アンチセンスオリゴヌクレオチド（ａｓｏ）およびそれを使用する方法
WO2026080323A1 (en)	2024-10-09	2026-04-16	Quralis Corporation	Treatment of neurological diseases using modulators of unc13a gene transcripts

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5276019A (en) *	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
IT1230576B (it) *	1988-10-20	1991-10-28	Angeli Inst Spa	Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1246382B (it)	1990-04-17	1994-11-18	Eurand Int	Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP2916978B2 (ja) *	1993-08-25	1999-07-05	エスエス製薬株式会社	放出開始制御型製剤
DE69433817T2 (de)	1993-09-24	2005-07-14	Advanced Immuni T, Inc.	Lineare und cyklische peptide zur behandlung oder vorbeugung der crohn'schen krankheit und/oder der ulzerativen kolitis
WO1997045091A2 (en)	1996-05-31	1997-12-04	Euro-Celtique, S.A.	Sustained release oxycodone formulations with no fed/fast effect
WO1998049348A1 (en)	1997-04-30	1998-11-05	Isis Pharmaceuticals, Inc.	Oligonucleotides for enhanced bioavailability
IE970794A1 (en) *	1997-09-24	2000-08-23	Elan Corp Plc	Composition and method for enhancing paracellular transport across cell layers
US7341741B1 (en)	1997-09-26	2008-03-11	Jean-Pierre Sachetto	Pharmaceutical composition for the treatment of inflammatory bowel disease
US7192589B2 (en) *	1998-09-16	2007-03-20	Genentech, Inc.	Treatment of inflammatory disorders with STIgMA immunoadhesins
JPH11335269A (ja) *	1998-05-19	1999-12-07	Hisamitsu Pharmaceut Co Inc	遺伝子関連医薬の経口投与固形製剤
CA2329130A1 (en)	1998-05-21	1999-11-25	Isis Pharmaceuticals Inc.	Compositions and methods for non-parenteral delivery of oligonucleotides
JP4210454B2 (ja) *	2001-03-27	2009-01-21	日本たばこ産業株式会社	炎症性腸疾患治療剤
US6159697A (en) *	2000-01-19	2000-12-12	Isis Pharmaceuticals, Inc.	Antisense modulation of Smad7 expression
US20030124196A1 (en) *	2001-08-22	2003-07-03	Susan Weinbach	Pulsatile release compositions and methods for enhanced intestinal drug absorption
SI1456380T1 (sl)	2001-11-02	2012-11-30	Giuliani Int Ltd	Smad inhibitorji za zdravljenje cns bolezni
ZA200502318B (en) *	2002-10-16	2006-11-29	Takeda Pharmaceutical	Controlled release preparation
US20040224020A1 (en) *	2002-12-18	2004-11-11	Schoenhard Grant L.	Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
ITRM20030149A1 (it)	2003-04-02	2004-10-03	Giuliani Spa	Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
PT2446881E (pt) *	2003-07-24	2014-06-11	Glaxosmithkline Llc	Películas de dissolução oral
ITRM20030393A1 (it)	2003-08-11	2005-02-12	Giuliani Spa	Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
RU2375047C2 (ru)	2004-03-26	2009-12-10	Лек Фармасьютиклз Д.Д.	Фармацевтическая лекарственная форма, устойчивая к действию желудочного сока, включающая n-(2-(2-фталимидоэтокси)ацетил)-l-аланил-d-глутаминовую кислоту (lk 423)
WO2006056078A1 (en)	2004-11-26	2006-06-01	Medicure International Inc.	Novel formulation of pyridoxal 5'-phosphate and method of preparation
CN101151035A (zh) *	2004-12-02	2008-03-26	Isis制药公司	用于治疗炎性肠病的治疗性反义寡核苷酸组合物
US20060258610A1 (en) *	2005-05-12	2006-11-16	Isis Pharmaceuticals, Inc.	Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
WO2007016350A2 (en)	2005-07-28	2007-02-08	Supernus Pharmaceuticals, Inc.	Modified release tablet formulations with enhanced mechanical properties
WO2007047553A2 (en)	2005-10-14	2007-04-26	Zweig Jack I	Methods and compositions for treatment of prostate intraepithelial neoplasia
CN1850135A (zh) *	2006-03-09	2006-10-25	陈世忠	一种鸦胆子油肠溶软胶囊制剂及其制备方法和其应用
GB0607534D0 (en) *	2006-04-13	2006-05-24	Univ London Pharmacy	Colonic drug delivery formulation
EP2061440A2 (en) *	2007-04-04	2009-05-27	Sigmoid Pharma Limited	A pharmaceutical composition of tacrolimus
ES2627745T3 (es) *	2008-11-13	2017-07-31	Nogra Pharma Limited	Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
US9364495B2 (en) *	2009-10-20	2016-06-14	Roche Innovation Center Copenhagen A/S	Oral delivery of therapeutically effective LNA oligonucleotides
US9791442B2 (en)	2011-09-15	2017-10-17	Nogra Pharma Limited	Methods of monitoring responsiveness to anti-SMAD7 therapy
CN104487574B (zh)	2012-04-18	2017-07-07	诺格尔制药有限公司	治疗糖尿病和/或促进胰岛移植后存活的方法
EP2970419B8 (en)	2013-03-15	2019-12-11	Nogra Pharma Limited	Methods of treating colorectal cancer
US10006029B2 (en)	2013-03-15	2018-06-26	Nogra Pharma Limited	Methods of treating colorectal cancer
RU2016147569A (ru)	2014-05-09	2018-06-13	Ногра Фарма Лимитед	Способы лечения воспалительного заболевания кишечника
EP3174895A1 (en)	2014-07-28	2017-06-07	Nogra Pharma Limited	Methods and compositions for diagnosing and treating inflammatory bowel disorders
EP3213070A2 (en)	2014-10-17	2017-09-06	Nogra Pharma Limited	Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US10337004B2 (en)	2014-10-17	2019-07-02	Nogra Pharma Limited	Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
WO2017055611A2 (en)	2015-09-30	2017-04-06	Nogra Pharma Limited	Methods of using smad7 antisense oligonucleotides based on biomarker expression
JP2019507755A (ja)	2016-02-24	2019-03-22	ノグラファーマリミテッド	Ｓｍａｄ７阻害を使用するセリアック病の処置の方法
WO2018122376A1 (en)	2016-12-30	2018-07-05	Nogra Pharma Limited	Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

2009
- 2009-11-13 ES ES09756431.4T patent/ES2627745T3/es active Active
- 2009-11-13 FI FIEP16187284.1T patent/FI3121280T3/fi active
- 2009-11-13 NZ NZ592673A patent/NZ592673A/xx unknown
- 2009-11-13 EP EP09756431.4A patent/EP2364360B1/en active Active
- 2009-11-13 SI SI200932213T patent/SI3121280T1/sl unknown
- 2009-11-13 RS RS20170564A patent/RS56049B1/sr unknown
- 2009-11-13 HR HRP20250744TT patent/HRP20250744T1/hr unknown
- 2009-11-13 SM SM20250239T patent/SMT202500239T1/it unknown
- 2009-11-13 CN CN200980145188.6A patent/CN102216458B/zh active Active
- 2009-11-13 MX MX2015003911A patent/MX346335B/es unknown
- 2009-11-13 DK DK16187284.1T patent/DK3121280T3/da active
- 2009-11-13 HR HRP20170926TT patent/HRP20170926T1/hr unknown
- 2009-11-13 CA CA3085272A patent/CA3085272A1/en active Pending
- 2009-11-13 RS RS20250613A patent/RS66973B1/sr unknown
- 2009-11-13 PT PT161872841T patent/PT3121280T/pt unknown
- 2009-11-13 CN CN201710263782.1A patent/CN107007616A/zh active Pending
- 2009-11-13 SI SI200931677T patent/SI2364360T1/sl unknown
- 2009-11-13 KR KR1020117013391A patent/KR101767145B1/ko active Active
- 2009-11-13 LT LTEP09756431.4T patent/LT2364360T/lt unknown
- 2009-11-13 US US13/129,205 patent/US8912154B2/en active Active
- 2009-11-13 PL PL09756431T patent/PL2364360T3/pl unknown
- 2009-11-13 JP JP2011535922A patent/JP5719776B2/ja active Active
- 2009-11-13 PL PL16187284.1T patent/PL3121280T3/pl unknown
- 2009-11-13 MX MX2011005042A patent/MX2011005042A/es active IP Right Grant
- 2009-11-13 KR KR1020177021816A patent/KR101921014B1/ko active Active
- 2009-11-13 ES ES16187284T patent/ES3034412T3/es active Active
- 2009-11-13 AU AU2009315898A patent/AU2009315898B2/en not_active Ceased
- 2009-11-13 RU RU2011123876/10A patent/RU2593939C2/ru active
- 2009-11-13 WO PCT/EP2009/008087 patent/WO2010054826A1/en not_active Ceased
- 2009-11-13 PT PT97564314T patent/PT2364360T/pt unknown
- 2009-11-13 SM SM20170346T patent/SMT201700346T1/it unknown
- 2009-11-13 EP EP16187284.1A patent/EP3121280B1/en active Active
- 2009-11-13 HU HUE09756431A patent/HUE032368T2/en unknown
- 2009-11-13 HU HUE16187284A patent/HUE071668T2/hu unknown
- 2009-11-13 LT LTEP16187284.1T patent/LT3121280T/lt unknown
- 2009-11-13 DK DK09756431.4T patent/DK2364360T3/en active
- 2009-11-13 CA CA2743329A patent/CA2743329C/en active Active
- 2009-11-13 RU RU2016127232A patent/RU2739302C2/ru active
2011
- 2011-05-12 MX MX2023008408A patent/MX2023008408A/es unknown
2014
- 2014-07-16 JP JP2014145605A patent/JP2014196356A/ja not_active Withdrawn
- 2014-12-15 US US14/570,293 patent/US9314434B2/en active Active
- 2014-12-15 US US14/570,313 patent/US9499819B2/en active Active
2015
- 2015-09-16 JP JP2015182496A patent/JP6095744B2/ja not_active Expired - Fee Related
- 2015-10-21 AU AU2015246097A patent/AU2015246097B2/en active Active
2016
- 2016-04-15 US US15/130,737 patent/US9982264B2/en active Active
- 2016-10-26 US US15/335,198 patent/US10272047B2/en active Active
2017
- 2017-02-03 JP JP2017018231A patent/JP6530772B2/ja active Active
- 2017-06-12 CY CY20171100611T patent/CY1119140T1/el unknown
- 2017-12-19 AU AU2017279624A patent/AU2017279624B2/en not_active Ceased
2019
- 2019-01-15 US US16/248,414 patent/US20190374472A1/en not_active Abandoned
- 2019-05-17 JP JP2019093866A patent/JP7377624B2/ja active Active
2020
- 2020-04-29 AU AU2020202813A patent/AU2020202813A1/en not_active Abandoned
2021
- 2021-01-29 US US17/162,226 patent/US20210290656A1/en not_active Abandoned
- 2021-06-21 JP JP2021102423A patent/JP2021138778A/ja active Pending
2023
- 2023-08-09 JP JP2023130212A patent/JP2023138750A/ja active Pending

Also Published As

Publication number	Publication date
KR20110086599A (ko)	2011-07-28
CN102216458B (zh)	2017-05-24
MX346335B (es)	2017-03-14
PT2364360T (pt)	2017-06-27
US20150232854A1 (en)	2015-08-20
JP2012508705A (ja)	2012-04-12
EP3121280A1 (en)	2017-01-25
EP2364360B1 (en)	2017-03-22
ES2627745T3 (es)	2017-07-31
MX2023008408A (es)	2023-10-19
JP5719776B2 (ja)	2015-05-20
JP7377624B2 (ja)	2023-11-10
US20120015033A1 (en)	2012-01-19
US20160222383A1 (en)	2016-08-04
PL2364360T3 (pl)	2017-09-29
LT3121280T (lt)	2025-07-25
ES3034412T3 (en)	2025-08-18
SI3121280T1 (sl)	2025-08-29
DK2364360T3 (en)	2017-06-19
AU2017279624B2 (en)	2020-02-06
HRP20170926T1 (hr)	2017-09-22
HRP20250744T1 (hr)	2025-08-15
HUE032368T2 (en)	2017-09-28
AU2009315898A1 (en)	2010-05-20
LT2364360T (lt)	2017-08-10
RU2016127232A (ru)	2018-12-06
US9982264B2 (en)	2018-05-29
NZ592673A (en)	2013-01-25
JP2015232039A (ja)	2015-12-24
US10272047B2 (en)	2019-04-30
AU2015246097B2 (en)	2018-01-18
US20190374472A1 (en)	2019-12-12
CA2743329A1 (en)	2010-05-20
CN102216458A (zh)	2011-10-12
FI3121280T3 (fi)	2025-07-02
DK3121280T3 (da)	2025-06-30
CN107007616A (zh)	2017-08-04
JP2017075184A (ja)	2017-04-20
US20210290656A1 (en)	2021-09-23
US8912154B2 (en)	2014-12-16
WO2010054826A1 (en)	2010-05-20
RU2593939C2 (ru)	2016-08-10
JP2014196356A (ja)	2014-10-16
JP6530772B2 (ja)	2019-06-12
RU2739302C2 (ru)	2020-12-22
KR101767145B1 (ko)	2017-08-11
HUE071668T2 (hu)	2025-09-28
SMT201700346T1 (it)	2017-09-07
AU2009315898B2 (en)	2015-07-23
AU2015246097A1 (en)	2015-11-12
US20170107520A1 (en)	2017-04-20
US9314434B2 (en)	2016-04-19
US9499819B2 (en)	2016-11-22
CA3085272A1 (en)	2010-05-20
SMT202500239T1 (it)	2025-09-12
US20150125523A1 (en)	2015-05-07
RU2011123876A (ru)	2012-12-20
KR101921014B1 (ko)	2018-11-21
RS56049B1 (sr)	2017-09-29
JP2021138778A (ja)	2021-09-16
JP2023138750A (ja)	2023-10-02
JP6095744B2 (ja)	2017-03-15
RU2016127232A3 (pl)	2019-12-18
CA2743329C (en)	2020-09-01
CY1119140T1 (el)	2018-02-14
SI2364360T1 (sl)	2017-08-31
AU2017279624A1 (en)	2018-01-18
RS66973B1 (sr)	2025-07-31
JP2019151658A (ja)	2019-09-12
KR20170092719A (ko)	2017-08-11
EP3121280B1 (en)	2025-04-09
EP2364360A1 (en)	2011-09-14
AU2020202813A1 (en)	2020-05-21
PT3121280T (pt)	2025-07-01
MX2011005042A (es)	2011-08-17

Publication	Publication Date	Title
PL3812360T3 (pl)	2024-04-08	Związki monochlorotrifluoropropenu oraz kompozycje i sposoby ich zastosowania
PT2364360T (pt)	2017-06-27	Composições em sentido reverso e métodos de as fabricar e utilizar
IL252119B (en)	2019-06-30	Improved cell composition and methods of making the same
PT2424372T (pt)	2018-04-19	Composições antimicrobianas e métodos de uso relacionados
BRPI0913086A2 (pt)	2015-08-04	Composições antimicrobianas e métodos de uso
BRPI1008280A2 (pt)	2015-08-25	Formulações prebióticas e métodos mde uso
PL2624702T3 (pl)	2016-09-30	Kompozycje przeciwko tworzeniu biofilmów oraz sposoby ich zastosowania
SMT201500212B (it)	2015-10-30	Composizioni di antagonisti di pd-1 e metodi di utilizzo
EP2515946A4 (en)	2015-10-07	NANOCONJUGATE AND NANOCONJUGATE FORMULATIONS
BRPI0906980A2 (pt)	2015-07-21	Composição de derivados e maleatados
PL2963031T3 (pl)	2019-08-30	Proleki tetrahydrokannabinolu, kompozycje zawierające proleki tetrahydrokannabinolu i sposoby ich stosowania
BRPI1005670A2 (pt)	2017-03-28	composições adjuvantes e métodos de uso
IL208858A0 (en)	2011-01-31	Lipid-containing compositions and methods of use thereof
PL3178490T3 (pl)	2022-08-01	Kompozycje białka f rsv i sposoby ich wytwarzania
EP2334185A4 (en)	2011-09-21	COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
PL2346327T3 (pl)	2016-07-29	Kompozycje biobójcze i sposoby stosowania
EP2231665A4 (en)	2012-04-25	NEW COMPOSITIONS AND METHODS OF USE
PT3278665T (pt)	2020-11-19	Composição farmacêutica estável e métodos de utilização das mesmas
BRPI0917707A2 (pt)	2017-05-30	composições biocidas potencializadas e métodos de uso
IL201364A0 (en)	2010-06-30	Gas-effusing compositions and methods of making and using same
IL247929B (en)	2018-01-31	Stable compositions of 595–sns and methods for their preparation
ZA201102207B (en)	2011-11-30	Cinnamandehyde-allicin compositions and their method of use
IL207827A0 (en)	2010-12-30	Apoaequorin-containing compositions and methods of using same
EP2381950A4 (en)	2012-08-22	COMPOSITIONS AND METHOD FOR THEIR USE
BRPI1010278A2 (pt)	2017-05-16	composições para preparação do intestino e métodos de uso destas